Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of [18F]MK-6240 PET Imaging in Alzheimer's Disease
NCT02562989Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of florquinitau in Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants With Adverse Events (AEs) up to 16 weeks, Number of Participants Who Discontinued Study Due to an AE up to 16 weeks and 4 more. Started Oct 2015; status: completed.
02
Drugs
florquinitau
03
Conditions
Alzheimer's disease (AD)amnestic mild cognitive impairment (MCI)
Beyond the preview
Go deeper on NCT02562989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562989.